Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are recommended for the medium-to long-term management of knee osteoarthritis (OA) due to their abilities to control pain, improve function and delay joint structural changes. Among SYSADOAs, evidence is greatest for the patented crystalline glucosamine sulfate (pCGS) formulation (Mylan). Glucosamine is widely available as glucosamine sulfate (GS) and glucosamine hydrochloride (GH) preparations that vary substantially in molecular form, pharmaceutical formulation and dose regimen. Only pCGS is given as a highly bioavailable once-daily dose (1500 mg), which consistently delivers the plasma levels of around 10 lmol/L required to inhibit interleukin-1-induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction. Careful consideration of the evidence base reveals that only pCGS reliably provides a moderate effect size on pain that is higher than paracetamol and equivalent to non-steroidal anti-inflammatory drugs (NSAIDs), while non-crystalline GS and GH fail to reach statistical significance for pain reduction. Chronic administration of pCGS has disease-modifying effects, with a reduction in need for total joint replacement lasting for 5 years after treatment cessation. Pharmacoeconomic studies of pCGS demonstrate long-term reduction in additional pain analgesia and NSAIDs, with a 50% reduction in costs of other OA medication and healthcare consultations. Consequently, pCGS is the logical choice, with demonstrated medium-term control of pain and lasting impact on disease progression. Physician and patient education on the differentiation of pCGS from other glucosamine formulations will help to improve treatment selection, increase treatment adherence, and optimize clinical benefit in OA.
INTRODUCTION
Most of the OA disability burden is attributable to the hip and knee, of which knee OA is the more frequent. Knee and hip OA ranked as the 11th highest contributor to global disability in 2010 (measured as 17 million years lived with disability). 1 It is estimated that one in 10 of the population aged 60 years or older has significant clinical problems that can be attributed to OA. 2 Knee and hip OA are major contributors to global disability-adjusted life years (DALYs), with the Asian regions contributing to a large proportion of the disability; mean DALYs were estimated at 4.4 billion for East Asia, 2.5 billion for South Asia and 1.2 billion for Southeast Asia in 2010. 1 The prevalence of OA increases with age and generally affects women more frequently than men. 1 The prevalence of self-reported and/or symptomatic knee OA in European Health Surveys ranges from 4% to 20%, with rates of 30% to 50% among those aged ≥ 65 years. 2 By comparison, the Community-Oriented Program for the Control of Rheumatic Diseases (COP-CORD) studies conducted in the Asian region provide estimates of the prevalence of knee pain ranging from 11% in those aged > 45 years to 22% in those aged > 55 years, and 24-41% in those aged > 65 years among populations in the Philippines and Vietnam. 3 The prevalence of a diagnosis of knee OA ranges from 1% to 6% in both urban and rural populations of Thailand, Malaysia, the Philippines and Vietnam, and is likely to be an underestimate of OA prevalence if reliant on radiographically confirmed diagnosis. 3 The proportion of people aged ≥ 65 years in Asia is estimated to double in the next two decades, from 7% in 2008 to 16% in 2040 3 and the proportion of people aged ≥ 65 years will increase by more than 250% in Singapore, Malaysia and the Philippines. 3 OA has been associated with heavy physical occupational activity, a required livelihood for many people living in rural communities in developing countries. Unfortunately, joint replacement surgery, an effective intervention for people with severe OA involving the hips or knees, is inaccessible to most people in these regions. 3 Traditionally, the pharmacological management of OA has focused on therapies that may improve or control symptoms, or at least provide rescue analgesia. More recently, the use of symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), in particular prescription glucosamine sulfate (GS) and chondroitin sulfate (CS), has been proposed as a first-line pharmacological treatment for slow-onset medium to long-term control of symptoms in OA. 4 SYSADOAs have demonstrated symptomatic effects as well as potential disease-modifying effects, based upon reports of downregulation in the expression of several inflammatory and degenerative mediators resulting in an effect on pain and symptoms and also a slower degradation of the cartilage, hence preventing disease progression. 5 The clinical impact of this molecular mechanism has been observed as a reduction of pain and increased function, and radiological measurement of reduced joint space narrowing (JSN). 6, 7 While multiple international evidence-based guidelines for OA management exist, agreement on the different treatment modalities is lacking. [8] [9] [10] [11] [12] The main source of disagreement regarding the use of SYSADOAs derives from the fact that the regulatory status and, subsequently, the availability and labeling of these medications substantially differ in separate countries and regions of the world. 13 Glucosamine, in particular, is available on prescription as patented crystalline glucosamine sulfate (pCGS) (Mylan), 14 as generic and over-the-counter (OTC) formulations of GS and in food supplements mostly containing the glucosamine hydrochloride (GH) salt. Glucosamine generics, OTC products and food/nutritional supplements vary substantially from pCGS in their molecular forms, pharmaceutical formulation and dose regimens. Only prescription-grade pCGS is given as a highly bioavailable once-daily dose (1500 mg) with a proven pharmacological effect. 15 The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) has recently developed a treatment algorithm recommendation that helps the prescribing physician to prioritize interventions in the management of knee OA, which is based upon the available evidence and is applicable across Europe and internationally. 4 As a step 1 therapy, the ESCEO guidelines recognize that glucosamine is available in many forms, and yet not all formulations of glucosamine provide equivalent effects. Thus, the ESCEO task force recommends that pCGS should be differentiated from other glucosamine preparations due to a clear divergence in the evidence base. 4 In this review article, we have set out the evidence for the differentiation of pCGS from other glucosamine formulations. Publication of this review will serve to educate and inform physicians as to this difference; however, we are aware that patient education is an essential element of successful disease management. The ESCEO algorithm, along with other guidelines, recommends a core set of initial measures that each knee OA patient should undergo, including information access and education, weight loss if overweight and an appropriate exercise program. 4 The patient should be informed that while OA cannot as yet be cured, an improvement in symptoms and a control of disease progression may be obtained with the correct use of appropriate medications. Educating the patient on the difference between pCGS and the many other glucosamine formulations widely available will help to ensure treatment adherence to the correct formulation and maximize treatment outcomes.
GLUCOSAMINE: MECHANISM OF ACTION
Glucosamine is a naturally occurring building block for complex long-chain glycosaminoglycans that are linked to a core protein in proteoglycan molecules (aggrecans), and form part of the cartilage matrix. When administered exogenously, glucosamine exerts specific pharmacological effects on osteoarthritic cartilage and chondrocytes. 16, 17 Glucosamine inhibits gene expression of OA cartilage, and the anti-catabolic activities of glucosamine are responsible for its therapeutic effects. 18 GS is demonstrated in vitro to reduce prostaglandin E2 (PGE2) production and inhibit activation of the nuclear factor kappa-B (NFjB) pathway, thus inhibiting the cytokine intracellular signaling cascade in chondrocytes and synovial cells. [17] [18] [19] [20] In OA, glucosamine induces reversal of the pro-inflammatory and joint-degenerating effects of interleukin-1 (IL-1). 17 Interleukin-1 beta (IL-1b) is a potent pro-inflammatory cytokine produced in high amounts in the OA joint, where it triggers the expression of inflammatory factors such as cyclooxygenase-2 (COX-2), the inducible form of nitric oxide (iNOS), interleukin-6 (IL-6), and tumor necrosis factor a (TNFa). IL-1b also induces cells to produce more IL-1b as well as matrix degradation factors, such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member TSs (ADAM-TSs). Most of these genes are under the transcriptional control of NF-jB. Glucosamine at clinically relevant concentrations reduces COX-2, iNOS, and microsomal prostaglandin E synthase-1 (mPGEs1) gene expression and PGE2 synthesis after IL-1b stimulation, suggesting that glucosamine can control the cascade triggered by inflammatory stimuli. 21 These effects may be demonstrated in vitro with most glucosamine salts; however, pCGS is the only formulation for which these effects can be confirmed at the concentrations attained after administration of therapeutic doses in humans. pCGS inhibits IL-1-stimulated gene expression of joint degeneration mediators in human chondrocyte cells at concentrations in the range of 10 lmol/L, similar to those found in plasma or synovial fluid of knee OA patients after receiving pCGS at the therapeutic dose of 1500 mg once daily. 5 A dosedependent effect of pCGS on IL-1b-induced gene expression of matrix degradation factors MMP-3 (stromelysin-1) and ADAM-TS5 (aggrecanase 2) was observed. 5 Long-term oral administration of GS reduces the destruction of cartilage and upregulation of MMP-3 messenger RNA (mRNA) in in vitro models. 22 Furthermore, studies in a human osteoarthritic explant model demonstrate that GS is a stronger inhibitor of gene expression than GH, when both are administered at 5 mmol/L doses.
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GLUCOSAMINE: PHARMACOKINETICS
Studies measuring pharmacokinetic parameters demonstrate that a once daily dose of pCGS at 1500 mg leads to mean plasma concentration at a steady state of 9 lmol/L of glucosamine in healthy volunteers, 24 while administration of GH (500 mg thrice daily) leads to steady state levels of only 1.2 lmol/L (Table 1) . 25, 26 In a cross-over study, change from pCGS to GH resulted in a 50% decrease in peak plasma concentration and 75% reduction in total bioavailability, 15 which might be explained by the differences in dosing regimens and pharmaceutical formulations. The poor bioavailability obtained with GH may go some way to explain the poor results obtained with this formulation in the National Institutes of Health-supported GAIT study (Glucosamine/chondroitin Arthritis Intervention Trial), which failed to demonstrate any efficacy for GH versus placebo. 27 Importantly, in OA patients, peak glucosamine concentrations of 7.17 lmol/L (range 3.35-22.7) in the plasma and 4.34 lmol/L (range 3.22-18.1) in the synovial fluid have been measured at a steady state after once-daily administration of pCGS for 14 days (1500 mg). 28 The quality of non-pCGS glucosamine formulations may be sub-optimal 29 and a lack of appropriate stabilization of GS is shown to impact on the active ingredient availability. An investigation of 14 dietary supplements and OTC preparations of glucosamine found that only one contained the claimed amount of the active ingredient, while the others contained variable quantities ranging from 59% to 138% of the labeled dose. 29 The instability of glucosamine products other than pCGS has been observed in clinical practice in Asia. This may be due to the warm and humid climate conditions, which affects the chemical stability of some glucosamine formulations. Thus, only the pCGS formulation remains stable and reliably delivers sufficient plasma concentrations of glucosamine in the range that has been shown to be pharmacologically effective in reducing the expression of IL-1-induced cartilage degradation enzymes in human chondrocyte cultures.
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GLUCOSAMINE: EFFICACY
The treatment of OA is based upon primary pain and loss of function control; thus, numerous studies of varying qualities have been conducted to determine the effect of glucosamine on pain. A Cochrane review of 25 randomized controlled trials (RCTs) of all glucosamine formulations in 4963 OA patients, when limited to studies with adequate concealment, failed to show any benefit of glucosamine for pain. 30 However, when the RCTs using the pCGS formulation were analyzed in isolation, pCGS was found to be superior to placebo for pain (standardized mean difference [SMD] À1.11; 95% confidence interval [CI] À1.66 to À0.57) and function (Lequesne index SMD À0.47; 95% CI À0.82 to À0.12). Conversely, analysis of those RCTs using a non-pCGS preparation of glucosamine failed to reach statistical significance for pain or function. 30 For example, an 8-week RCT of GH versus placebo failed to meet the primary endpoint of a statistically significant difference in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score; however, favorable differences were found in the secondary endpoints of cumulative pain reduction as measured by a daily diary question (P = 0.018) and in the knee examination from week 5 though to week 8 (P = 0.026). 31 Proposed explanations for the difference in efficacy found between various glucosamine formulations have focused on the poor quality of some trials included in the meta-analyses and the potential risk of bias which may distort the results. A systematic quality assessment and meta-analysis of glucosamine and chondroitin preparations for OA symptoms initially found moderate to large effect sizes for both treatments, although only one study described adequate allocation concealment and the effects were diminished when only highquality or large trials were considered. 32 The Cochrane review found superiority for the pCGS formulation on pain in OA, but with high heterogeneity between trials (I 2 = 92%). 30 One solution is to focus only on the high-quality trials of glucosamine. A subgroup analysis in the Cochrane review of three pivotal RCTs found pCGS to be significantly superior to placebo in terms of WOMAC pain subscale score (SMD À0.17; 95% CI À0.32 to À0.01; P = 0.037), with zero heterogeneity between trials. 30 A stratified meta-analysis was performed by Eriksen and colleagues to address the potential risk of bias due to unsatisfactory handling of the data, that is, during randomization and concealment and statistical analyses. 33 They found that only eight studies met the standard for 'low risk of bias'. This analysis confirmed that the five studies with non-pCGS formulations even with a 'low risk of bias' found a non-significant effect on pain reduction (0.02; 95% CI À0.08 to 0.12). In contrast, analysis of the three 'low risk of bias' studies with pCGS confirmed a reduction in pain with effect size of 0.27 (95% CI À0.43 to À0.12). 6, 7, 33, 34 This recent finding is in total agreement with an earlier analysis of the same three RCTs of pCGS judged to be of highest quality using the Jadad quality score for clinical trials. 35, 36 In the absence of industry bias, several other factors may explain the difference in efficacy observed between quality clinical trials of glucosamine preparations. The superiority of pCGS may be explained by the unique stabilized formulation of glucosamine, single oncedaily dosing regimen (1500 mg) and high bioavailability, reaching higher glucosamine concentration in the plasma, compared with other preparations. 15 The impact of pCGS formulation on other symptom outcomes is demonstrated in further analysis of results from the pivotal three RCTs, with a significant effect size on WOMAC total score, WOMAC pain and function subscale scores, and Lequesne index, with a complete absence of heterogeneity (Fig. 1) . 26, 35 While the effect size for pCGS on pain may be considered as only moderate at 0.27, it is notable that pCGS has a greater effect on pain than that of paracetamol (with effect size of 0.14; 95% CI 0.05-0.22), 37 which may still be used as first-line rescue analgesia for OA. 4 In addition, the effect size of pCGS on pain over treatment periods ranging between 6 months and 3 years is equivalent to that achieved with oral nonselective or COX-2-selective non-steroidal anti-inflammatory drugs (NSAIDs), at 0.29 (95% CI 0.22-0.35) for much shorter treatment courses, 38 which are recommended as step 2 treatments in persistently symptomatic OA patients. 
GLUCOSAMINE: SAFETY
The balance of risk versus benefits must be considered prior to administration of all treatments. Oral NSAIDs are recommended for intermittent or cyclical use due to concerns over gastrointestinal (GI) and cardiovascular adverse events. 4 There is also accumulating evidence for an increased risk of GI adverse events with paracetamol use, with elevation in liver enzymes. 37 Conversely, pCGS may be taken safely in the long term with an adverse event rate comparable with that of placebo. 6, 7, 30, 33 In Thailand, the concomitant prescription of a COX-2 inhibitor plus pCGS is recommended for not more than 2 weeks due to safety concerns (related to the COX-2 inhibitor). In this case, an NSAID with an improved risk : benefit ratio may be considered, such as nabumetone, which is associated with a 10-fold lower risk of GI adverse events compared with other NSAIDs.
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GLUCOSAMINE: DISEASE-MODIFYING EFFECTS
Two RCTs provide evidence that the long-term administration of pCGS over 3 years delays joint structure changes, suggesting a potential benefit of pCGS beyond symptom control when used early in the treatment algorithm. 6, 7 Analysis of joint space width (JSW) at trial enrollment and after 3 years of treatment in the two RCTs of pCGS versus placebo demonstrates a reduction in JSN with pCGS. In one study, a significant difference in JSN of 0.33 mm (95% CI 0.12-0.54) was observed with pCGS versus placebo after 3 years (P = 0.003). 6 In the second study, pCGS treatment for 3 years was shown to completely prevent narrowing of the joint (JSN +0.04 mm; 95% CI À0.06 to 0.14: P = 0.001) ( Table 2) . 7, 26, 40 Subsequent analysis demonstrated that the relief of knee pain did not bias the report of a structure-modifying effect of pCGS in these two trials. 41 A lack of progression of JSN over 2-3 years (determined at a threshold of 0.5 mm [> 0.3-0.7 mm]) has demonstrated a predictive value of > 90% for not having joint replacement surgery 42 and is proposed as a surrogate marker for total joint replacement (TJR). 43 In two studies, fewer patients treated with pCGS experienced predefined severe JSN (> 0.5 mm) compared with patients treated with placebo. 6, 7 After 3 years, in the first study 30% of patients randomized to placebo had a severe mean JSN of > 0.5 mm compared with 15% with pCGS (P = 0Á013). 6 In the second study, the proportion of patients experiencing severe JSN was 14% in the placebo group and 5% in the pCGS group (P = 0.05). 7 Long-term follow-up of knee OA patients who had participated in the two 3-year RCTs of pCGS and received treatment for at least 12 months in a post hoc analysis revealed that TJR had occurred in over twice as many patients from the placebo group (14.5%) in the 5 years of follow up compared with those patients formerly receiving pCGS (6.3%; P = 0.024), Figure 1 Symptom outcomes for patented crystalline glucosamine sulfate (pCGS) formulation in knee osteoarthritis: pooled effect size from three pivotal trials. Adapted from Reginster. 35 Reproduced with permission from Kucharz et al.
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Estimates and 95% confidence intervals (CIs) from fixed-model meta-analysis method using the pooled standard deviation in each study/ outcome: 6, 7, 34 the data in the demonstrating a 57% reduction in risk of TJR with pCGS (relative risk 0.43; 95% CI 0.20-0.92). 40 Treatment with pCGS significantly delayed the need for TJR surgery (P = 0.026) (Fig. 2 ).
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GLUCOSAMINE: COST-EFFECTIVENESS
Few studies have considered the economic costs of OA in Southeast Asia. The economic burden of OA to society and patients was found to increase three-fold among patients who received total joint replacement surgery at the Singapore General Hospital. 45 The indirect cost of OA, including work absence and productivity loss, was estimated at around US$1000-1200 in Singapore, or around 3% of the annual household income. 45 The actual cost is likely to be higher as the estimate did not include caregiver burden. Further, the intangible cost of OA, calculated as the maximum amount a person would be willing to pay, sacrifice or exchange in order to avoid the pain and suffering of OA was estimated at US$1200 per year. 46 Six months treatment with pCGS is shown to be a highly cost-effective therapy compared with paracetamol and placebo in the treatment of knee OA, in terms of incremental cost-effectiveness ratio (ICER). 33, 47 The incremental cost per QALY gain for adding pCGS to current care over a lifetime horizon is estimated at around US$30,000. 48 The cost-effectiveness of pCGS therapy is dependent on the magnitude of the quality of life gain, the change in knee TJR probability and the discount rate.
The continuous use of pCGS results in a reduction in intake of other concomitant medication for OA and in a reduction in healthcare consultations and examinations, as demonstrated in a long-term follow up of OA patients. 44 A subset of patients who had previously taken part in an RCT attended a follow-up clinic visit at which the total average cost of OA-related resources per year was calculated to have approximately halved among those that had received pCGS versus placebo ((US$380 vs. US$786;; P = 0.024) (Table 3) . 26, 44 The total cost of OA medications taken among the placebo group (including analgesics and NSAIDs) was almost double that of the pCGS group (US$265 with placebo vs. US$140 with pCGS); while the number of specialist, general practitioner (GP) and paramedic visits, and examinations (radiographs, gastroscopies and non-OA examinations) were consistently higher among the placebo group compared with pCGS patients. 44 Evidence for a reduction in the need for rescue pain analgesia achieved with continuous pCGS is provided by a recent study, which is representative of all OA patients in everyday life. The Pharmaco-Epidemiology of GonArthroSis (PEGASus) study was conducted by the French Health Authorities in collaboration with a panel of French rheumatologists and epidemiologists; the primary objective of the study was to assess the impact of SYSADOAs on the use of NSAIDs. 49 Adults with knee and/or hip OA consulting a rheumatologist or GP for symptom flare were recruited into the PEGASus study and assigned to a SYSADOA treatment according to the physician's or patient's choice. During up to 24 months of follow up, SYSADOA switching, continuation or discontinuation was permitted. Among all SYSADOA treatments, including GH, CS, avocado soybean unsaponifiables and diacerein, in the primary analysis only pCGS achieved a significant reduction in NSAID use of 36% (odds ratio [OR] 0.64; 95% CI 0.45-0.92) (Fig. 3) . 49 The reduction in NSAID use was even greater, approaching a 50% reduction, when patients who received > 4 months of treatment with pCGS were considered alone (OR 0.52; 95% CI 0.28-0.95).
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CONCLUSIONS
Treatment goals for OA are to reduce symptoms and ultimately slow disease progression. In this respect, pCGS (1500 mg once daily) is the logical choice to optimize OA treatment with demonstrated mediumterm control of pain and lasting impact on disease progression. As well as a moderate effect on pain, chronic administration of pCGS over 12 months has disease-modifying effects, delaying joint structural changes and leading to a reduction in need for knee TJR surgery. There is also evidence for a reduction in the need for pain analgesia and NSAIDs with pCGS therapy over 12 months, with significant reduction in costs associated with medications, healthcare consultations and examinations. Finally, examination of the evidence base identifies that exposing patients to a non-pCGS glucosamine preparation (sulfate or HCl) which may not provide any clinical benefit might be considered a waste of economic resources both in terms of direct drug costs and increased utilization of healthcare systems. the version to be published. We are grateful to the following colleagues for their contributions to discussions during two ESCEO workshop meetings held in San Francisco, USA (7 November, 2015) and in Phuket, Thailand (14 November, 2015) and their review of this manuscript, which was written as a result of those meetings: Assoc. Prof. Thawee Songpatanasilp (Thailand), Dr. Loo Kok Lim (Malaysia), Prof. Ester Z. GonzalesPenserga (Philippines), Dr. Virginia Cabling (Philippines), Dr Japit Galagaran Jr. (Philippines), and Prof. Kyaw Myint Naing (Myanmar). In addition, we are grateful to Prof. Ester Gonzales-Penserga for her presentation of the Philippines Rheumatology Association (PRA) guidelines on the management of knee osteoarthritis at the Phuket meeting. Editorial assistance in the preparation of this manuscript was provided by 44 NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; pCGS, patented crystalline glucosamine sulfate.
Figure 3
Odds ratio (with 95% confidence interval) for NSAID use with symptomatic slow-acting osteoarthritis drugs in the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Adapted from Rovati et al. 49 CI, confidence interval; NSAID, non-steroidal anti-inflammatory drugs.
